Company intelligence / Profile preview

Biotherapy Services Limited

London, England, United Kingdombiotherapyservices.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Biotherapy Services’ RAPID™ Biodynamic Haematogel has received MHRA approval as a first-in-class point-of-care wound care treatment classified as a medicine. The RAPID-1DFU clinical trial began in March 2019 to assess safety and efficacy for diabetic foot ulcers. Early data show the product can concentrate platelets/leukocytes from patient blood to release growth factors that stimulate cell proliferation relevant to wound healing. The trial remains active at multiple UK sites

Therapeutic areas: EndocrinologyDermatology
Modalities: Autologous biological therapies (specifically autologous platelet and leukocyte-rich plasma gels)
Industry: Biotech

Partnerships

Foresight Group (private equity investor)Clinical sites including Royal London Hospital for trials

Beyond the preview

Go deeper on Biotherapy Services Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotherapy Services Limited.